Luseogliflozin (trade name Lusefi) is a pharmaceutical drug (an SGLT2 inhibitor) used for the treatment of type 2 diabetes mellitus. It was approved for use in Japan in 2014.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:alternativeName |
|
| dbo:casNumber |
|
| dbo:drugbank |
|
| dbo:fdaUniiCode |
|
| dbo:pubchem |
|
| dbo:thumbnail | |
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink | |
| dbp:atcPrefix |
|
| dbp:atcSuffix |
|
| dbp:c |
|
| dbp:casNumber |
|
| dbp:drugbank |
|
| dbp:h |
|
| dbp:legalStatus |
|
| dbp:o |
|
| dbp:pubchem |
|
| dbp:s |
|
| dbp:smiles |
|
| dbp:synonyms |
|
| dbp:tradename |
|
| dbp:unii |
|
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:depiction | |
| foaf:isPrimaryTopicOf | |
| is dbo:wikiPageRedirects of | |
| is dbo:wikiPageWikiLink of | |
| is foaf:primaryTopic of |
